Malignant lymphoma Malignant lymphoma, hyperglycemia
Conditions
Interventions
Administer duraglutide once a week
duraglutide
Sponsors
Suyama Takuya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients recieved R-CHOP therapy for malignant lymphoma (2) ECOG performance status score 0-2 (3) Patients dignosed with Type2 diabetes, or Patients who have been found twice by repeated tests of either fasting blood glucose of 126 mg / dl or more and blood glucose of 200 mg / dl or more during first chemotherapy (4) Patients who are not allergic to dulaglutide (5) Patients who have never used duraglutide before (6) Patients with written consent
Exclusion criteria
Exclusion criteria: (1) Patients with a history of hyperglycemic coma and diabetic ketoacidosis (2) Patients with type 1 diabetes (3) Patients judged by the researcher to be inappropriate as subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1C rate of change before treatment and 1.2.3.4.5.6 months after the start of dulaglutide | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) The incidence of hypoglycemia (2) Insulin consumption per body weight (3) Decrease in fasting blood glucose before treatment (4) Glycoalbumin change before treatment and 1.2.3.4.5.6 months after duraglutide | — |
Contacts
Public ContactTakuya Suyama
Hitachi general hospital
Outcome results
None listed